BCRX BIOCRYST PHARMACEUTICALS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882796 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.3%
TTM net income YoY-3,996.8%
TTM EPS YoY-2,460.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—
Margins
Gross margin97.9%
Operating margin-30.1%
Net margin-37.4%
FCF margin38.0%
EBITDA margin-29.9%
Returns
ROE—
ROA-69.3%
ROIC (approx.)—
Asset turnover1.85x
Leverage & solvency
Liabilities / assets167.2%
Debt / equity—
Current ratio2.71x
Interest coverage-3.77x
Cash quality & payout
Operating cash flow / net income-1.02x
Accruals ratio-140.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $874.84M | $450.71M |
| Cost of revenue | $19.07M | $12.27M |
| Gross profit | $855.76M | $438.44M |
| R&D expense | $166.13M | $174.64M |
| SG&A expense | $348.65M | $266.35M |
| Operating income | $340.99M | -$2.54M |
| Interest expense | $78.87M | $98.52M |
| Pretax income | $267.39M | -$86.95M |
| Income tax | $3.53M | $1.93M |
| Net income | $263.86M | -$88.88M |
| EBITDA | $342.38M | -$1.30M |
| EPS (basic) | 1.26 | -0.43 |
| EPS (diluted) | 1.21 | -0.43 |
| Weighted avg. shares (diluted) | 218.58M | 206.70M |
| Balance sheet | ||
| Cash & equivalents | $89.74M | $106.32M |
| Short-term investments | $185.01M | $216.14M |
| Receivables | $106.82M | $79.07M |
| Inventory | $5.40M | $8.09M |
| Current assets | $404.35M | $421.97M |
| PP&E, net | $8.78M | $7.78M |
| Total assets | $514.16M | $490.42M |
| Current liabilities | $196.07M | $160.38M |
| Long-term debt | $0 | $314.87M |
| Total debt | $0 | $314.87M |
| Total liabilities | $633.31M | $966.35M |
| Shareholders' equity | -$119.15M | -$475.93M |
| Net debt | -$89.74M | $208.55M |
| Shares outstanding | 213.06M | 208.54M |
| Cash flow statement | ||
| Operating cash flow | $347.37M | -$52.02M |
| Capital expenditure | $2.47M | $1.12M |
| Free cash flow | $344.90M | -$53.14M |
| Investing cash flow | -$13.69M | $52.59M |
| Financing cash flow | -$349.93M | -$5.76M |
| Depreciation & amortization | $1.39M | $1.25M |
| Stock-based compensation | $85.07M | $65.41M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.